Combined OX40 ligation plus CTLA-4 blockade

• DOI: 10.4161/onci.28245
• Publication Date: 2014-05-02T14:37:26Z
• Authors: Stefanie N Linch; William L Redmond
• Keywords: CTLA-4; Augment; Cancer Immunotherapy

It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4 blockade in addition therapy significantly improved anti-tumor efficacy.